Laboratoris Sanifit S.A., is a clinical-stage biopharmaceutical company focused on the development of SNF472, a promising drug for the treatment of cardiovascular diseases linked to calcification in patients with End Stage Renal Disease (ESRD) undergoing hemodialysis.

ESRD patients treated with dialysis experience higher rates of serious cardiovascular adverse events and  mortality  as  a  consequence  of  accelerated  progression  of  cardiovascular calcification. Half of the mortality in dialysis patients is from cardiovascular complications. Calciphylaxis is the most severe form of cardiovascular calcification. It is a devastating rare disease that affects up to 4% of dialysis patients and has an overall mortality rate of about 80%. There are approximately 2.5 million dialysis patients worldwide with no effective treatment for this medical condition. ESRD represents a market opportunity of over €2Bn.

Gilde Healthcare invested alongside a syndicate of international investors in a €36.6M financing round. With the proceeds from this financing round Sanifit completed a phase 2 study with its lead drug candidate SNF-472 in calciphylaxis and will advance this drug candidate through phase IIb as a treatment for cardiovascular diseases linked to cardiovascular calcification in dialysis patients.

Sanifit  is located in Palma (Mallorca, Spain) and in San Diego (United States).



Palma de Mallorca, Spain